Leeven APL

Leeven APL is a specialized pharmaceutical company focused on the development and commercialization of treatments for acute promyelocytic leukemia (APL). The company is best known for its production of Tretinoin (all-trans retinoic acid), which serves as a cornerstone therapy in the induction of remission for APL patients. By targeting the underlying genetic drivers of the disease, Leeven APL provides critical therapeutic options that have significantly improved survival rates for this specific subtype of leukemia. The company operates primarily within the oncology space, maintaining a focused portfolio dedicated to hematological malignancies. Their work emphasizes the importance of differentiation therapy in treating rare and aggressive blood cancers.